TrialJournal for immunotherapy of cancer2026

Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses.

Yaohui Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.